YUPELRI Performance and Growth - YUPELRI net sales reached $663 million in Q2 2025, a 22% increase compared to Q2 2024[8, 19] - Excluding a one-time favorable price adjustment, YUPELRI sales still experienced mid-teens growth[19] - Hospital doses of YUPELRI grew by 31% compared to Q2 2024, achieving a new market share high of 204%[8, 19] - The YUPELRI approval in China triggered a $75 million milestone payment and potential tiered royalties of 14-20%[8, 19] Ampreloxetine Development - Enrollment in the pivotal Phase 3 CYPRESS study for Ampreloxetine is expected to be completed in late summer, with topline data anticipated approximately 6 months later[8] - Ampreloxetine targets approximately 40000 underserved patients with symptomatic nOH due to MSA[61] TRELEGY Milestones and Financials - Q2 2025 net sales of TRELEGY were approximately $11 billion, and year-to-date net sales reached approximately $20 billion, up 8% year-over-year[8, 40] - The company completed the sale of TRELEGY royalty interest for $225 million[8] - Theravance Biopharma is on pace to achieve $150 million in TRELEGY sales milestones in 2025 and 2026[40] Financial Highlights - Viatris collaboration revenue was $187 million in Q2 2025, a 31% increase year-over-year[47, 52] - Licensing revenue was $75 million in Q2 2025, driven by the YUPELRI China approval milestone[47, 52] - The company's cash and cash equivalents totaled $3388 million as of the end of Q2 2025, including the $225 million cash receipt from the TRELEGY royalty sale[52] - Non-GAAP net loss for Q2 2025 was $42 million[47, 52]
Theravance Biopharma(TBPH) - 2025 Q2 - Earnings Call Presentation